As the most reliable and balanced news aggregation service in the world, TTOA offers the following information published by: Daily Caller
A U.S. drug company hiked the price of its opioid overdose treatment over 600 percent since going to market in 2014, but the number of prescriptions filled for the drug skyrocketed.
Now the link between the drug’s price jump and drugmaker Kaleo’s ability to rake in cash from Medicare and other entities has been detailed in a Senate subcommittee investigation released Sunday evening.
Virginia-based Kaleo makes Evzio, an opioid overdose reversal drug containing naloxone. Naloxone is used in several kinds of opioid overdose treatments.
But Evzio is different for two reasons. The first is that the injector is extremely easy to use. It even talks users through the injection process. The second is because of how much it costs — as of November, two injectors of Evzio cost approximately $4,100, according to the subcommittee report
That’s compared to the $125 price tag for two doses of Narcan, a nasal spray that also contains naloxone.
The subcommittee report on Evzio centers on the arrival of consultant Todd Smith at Kaleo.
Click On “Next” Button Below to Continue Reading…